Last update Dec. 21, 2021
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Diclofenac Epolamine is also known as Diclofenac. Here it is a list of alternative known names::
Diclofenac Epolamine in other languages or writings:
Diclofenac Epolamine belongs to these groups or families:
Main tradenames from several countries containing Diclofenac Epolamine in its composition:
|Tmax||1 - 2||hours|
|T½||1 - 2||hours|
|Theoretical Dose||0.00075 - 0.015||mg/Kg/d|
|Relative Dose||0.03 - 0.9||%|
|Ped.Relat.Dose||0.025 - 3||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID). Indicated in rheumatic diseases, gout, dysmenorrhea, adnexitis, and post-traumatic or post-operative pain and inflammation. Oral administration in two to three daily doses. It can also be administered intramuscularly or intravenously.
Its pharmacokinetic data (high percentage of protein binding and short half-life) explain the zero or miniscule transfer into breastmilk observed: The drug is excreted in milk in insignificant or undetectable quantities. (AEMPS 2017, Sandoz 2017, Hale 2017 p.277, Hutchinson 2013, Worthington 2013, ABM 2012, Østensen 2007, Sioufi 1982)
No adverse effects have been detected in breastfed babies whose mothers were taking it. (Yefet 2017, Davanzo 2014, Hutchinson 2013, Hirose 1996)
For all these reasons it is considered compatible with breastfeeding. (Hale 2017 p277, Yefet 2017, Briggs 2015, Schaefer 2015, Davanzo 2014, Hutchinson 2013, Amir 2011, Nice 2004, Lee 1993, Brooks 1990, Goldsmith 1989, Needs 1985)
Most non-steroidal anti-inflammatories can increase jaundice, so it is preferable to avoid them during the neonatal period in mothers of jaundiced infants. (Janssen 2000)
TOPICAL USE: The small dose and poor plasma uptake of most topical dermatological or ophthalmological preparations make it very unlikely that significant amounts will pass into breast milk. Ophthalmic or dermatological use is completely compatible with breastfeeding.